BIND, Amgen collaborate on solid tumor drug development

01/9/2013 | American City Business Journals

Amgen and BIND Biosciences agreed to develop a drug for solid tumors using the latter's technology platform. The partners hope to develop a new class of drug that would be more effective and less toxic than existing chemotherapy treatments. BIND could potentially receive up to $180.5 million in upfront and milestone fees, plus royalties.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA